Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal Evolution
- PMID: 40029262
- PMCID: PMC12081191
- DOI: 10.1158/1078-0432.CCR-24-2040
Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal Evolution
Abstract
Purpose: Ewing sarcoma is the second most common bone cancer in children, accounting for 2% of pediatric cancer diagnoses. Patients who present with metastatic disease at the time of diagnosis have a dismal prognosis compared with the >70% 5-year survival of those with localized disease. Novel therapeutic approaches that can impact metastatic disease are desperately needed, as well as a deeper understanding of the heterogeneity of Ewing sarcoma tumors.
Experimental design: In this study, we utilized single-cell RNA sequencing to characterize the transcriptional landscape of primary Ewing sarcoma tumors and the surrounding tumor microenvironment in a cohort of seven untreated patients with Ewing sarcoma, as well as in circulating tumor cells (CTC). A potential CTC therapeutic target was evaluated through immunofluorescence of fixed CTCs from a separate cohort.
Results: Primary tumor samples demonstrate a heterogeneous transcriptional landscape with several conserved gene expression programs, including those composed of genes related to proliferation and Ewing sarcoma gene targets, which were found to correlate with overall survival. Copy-number analysis identified subclonal evolution within patients prior to treatment. Analyses of the immune microenvironment reveal an immunosuppressive microenvironment with complex intercellular communication among the tumor and immune cells. Single-cell RNA sequencing and immunofluorescence of CTCs at the time of diagnosis identified TSPAN8 as a potential therapeutic target.
Conclusions: Ewing sarcoma tumors demonstrate significant transcriptional heterogeneity as well as a complex immunosuppressive microenvironment. This work evaluates several proposed targets that warrant further exploration as novel therapeutic strategies.
©2025 American Association for Cancer Research.
Conflict of interest statement
References
-
- Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, et al. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov 2014;4(11):1326–41 doi 10.1158/2159-8290.CD-13-1037. - DOI - PubMed
-
- Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. Cancer Discov 2014;4(11):1342–53 doi 10.1158/2159-8290.CD-14-0622. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
- P30CA046934/National Cancer Institute (NCI)
- Young Investigator Award/Hyundai Hope On Wheels (Hope On Wheels)
- K12HD068372/Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- K12 HD068372/HD/NICHD NIH HHS/United States
- CA200508/Congressionally Directed Medical Research Programs (CDMRP)
LinkOut - more resources
Full Text Sources
Medical
